# PharmEnable

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmenable

- Industry: Biotechnology
- Headquarters: Cambridge, UK
- Website: www.pharmenable.com
- Total disclosed funding: $2.3M
- Latest round: Seed (Apr 29, 2020)
- Investors on record: 4

## About

Based in Cambridge, UK, and founded in 2016 by CEO Hannah Sore, Jelena Aleksic, and Natalia Mateu, PharmEnable Ltd., a.k.a PharmEnable operates as a biopharmaceutical company that integrates advanced medicinal chemistry expertise and AI (artificial intelligence) to deliver novel therapeutics for diseases with high clinical need. In May 2023, PharmEnable Ltd. raised USD 7.5 million in venture funding led by MP Healthcare Venture Management, with participation from Cambridge Enterprise, Parkwalk Advisors, Heyford Group, O2h Ventures, Martlet Capital, Arrowfield Capital, and Wren Capital.

The company provides leverages its platform known as chemSAILOR, an intelligent cheminformatics system that blends human ingenuity with AI algorithms for the identification of suitable regions of chemical space and suggests optimal synthetic options to create active molecules against specific biological targets. Additionally, the company utilizes chemUNIVERSE, a proprietary accessible chemical space, comprising novel virtual compounds that cover a broad range of complexity and diversity.

PharmEnable plans to use its proceeds from May 2023 funding to advance and expand its portfolio of wholly owned and co-discovery projects around targets in cancer and neurology.

## Funding rounds

- Seed, Apr 29, 2020, $2.3M — Cambridge Enterprise, Parkwalk Advisors, Wren Capital, O2h Ventures

## Investors

- Cambridge Enterprise — Seed
- Parkwalk Advisors (https://capitalatlas.ai/funds/parkwalk-advisors) — Seed
- Wren Capital (https://capitalatlas.ai/funds/wren-capital) — Seed
- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Seed